Chief Executive Officer · PDS Biotechnology Corp (PDSB)

Frank Bedu-Addo

A named executive officer of PDS Biotechnology in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$828,307

Salary $615,322Stock awards $0

FY2024: $2,263,569

1st of 3 named executive officers at PDS Biotechnology by FY2025 total.

3 named officers on file for PDS Biotechnology, FY2025

Frank Bedu-Addo’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how PDS Biotechnology’s whole pay program stands against its peers

  • PDS Biotechnology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PDSB→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 26, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Frank Bedu-Addo’s full pay file as a PDF — free

More than this page: up to 10 years of Frank’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Frank Bedu-Addo compensation by year

PDS Biotechnology Summary Compensation Table · all 2 fiscal years held
In US dollars, as PDS Biotechnology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$597,000$615,322
Bonus$0$0
Stock awards$0$0
Option awards$1,647,000$193,500
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$19,169$19,485
Total$2,263,569$828,307

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PDS Biotechnology Corp DEF 14A filed June 26, 2026, accession 0001140361-26-026564, and prior-year filings. Open the filing on EDGAR.

How this page was built: the PDS Biotechnology Corp filed document, accession 0001140361-26-026564. Every figure is read from that document and cited to the page and table it appears in. Filed June 26, 2026.

$2.3M
$828K
FY24
FY25
SalaryOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU300,000$230,940—
Option150,000—$1.79
Option161,918—$5.87
Option97,381—$11.61
Option3,594—$6.28

Per the Outstanding Equity Awards at Fiscal Year-End table in PDS Biotechnology Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2025 proxy (filed June 26, 2026)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-16Grant or award derivative—2,698,978$0.002,698,978
2026-11-16Grant or award derivative—16,556,733$0.0016,556,733

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

PDS Biotechnology’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Frank Bedu-Addo · this pageChief Executive Officer$828,307
Kirk ShepardChief Medical Officer$677,318
Stephan ToutainChief Operating Officer$673,629

The full PDS Biotechnology compensation record

free company brief

This page is one person within PDS Biotechnology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PDS Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Frank Bedu-Addo's compensation dossier · One-time report. No refunds.